[1]任江艳,王新星,王向阳,等.血清miR-193b-3p与动脉瘤性蛛网膜下腔出血病人不良预后的关系[J].中国临床神经外科杂志,2023,28(09):569-572.[doi:10.13798/j.issn.1009-153X.2023.09.007]
　REN Jiang-yan,WANG Xin-xing,WANG Xiang-yang,et al.Relationship between serum miR-193b-3p on admition and poor prognosis of patients with aneurysmal subarachnoid hemorrhage[J].,2023,28(09):569-572.[doi:10.13798/j.issn.1009-153X.2023.09.007]
点击复制

血清miR-193b-3p与动脉瘤性蛛网膜下腔出血病人不良预后的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年09期
页码:
569-572
栏目:
论著
出版日期:
2023-09-30

文章信息/Info

Title:
Relationship between serum miR-193b-3p on admition and poor prognosis of patients with aneurysmal subarachnoid hemorrhage
文章编号:
1009-153X（2023）09-0569-04
作者:
任江艳; 王新星; 王向阳; 仝海波; 任晓佳
030012太原，山西白求恩医院神经外科（任江艳、王新星、王向阳、仝海波、任晓佳）
Author(s):
REN Jiang-yan;  WANG Xin-xing;  WANG Xiang-yang;  TONG Hai-bo;  REN Xiao-jia
Department of Neurosurgery, Shanxi Bethune Hospital, Taiyuan 030012, China
关键词:
动脉瘤性蛛网膜下腔出血; 微小核糖核酸; miRNA; miR-193b-3p; 血清; 预后
Keywords:
Aneurysmal subarachnoid hemorrhage;  Serum;  miR-193b-3p;  Prognosis
分类号:
R 743.9
DOI:
10.13798/j.issn.1009-153X.2023.09.007
文献标志码:
A
摘要:
目的 探讨血清微小核糖核酸（miR）-193b-3p与动脉瘤性蛛网膜下腔出血（aSAH）病人不良预后的关系。方法 2019年1月1日至2021年12月1日前瞻性收集aSAH共159例，采用RT-PCR检测入院24 h内血清miR-193b-3p水平。发病90 d，采用GOS评分评估预后，其中4~5分为预后良好，1~3分为预后不良。结果 159例中，预后良好153例，预后不良56例（35.2%），其中死亡39例。ROC曲线分析显示，入院24 h内血清miR-193b-3p水平预测aSAH不良预后的曲线下面积为0.912（95% CI 0.870~0.954），最佳截断值为0.62，灵敏度和特异度分别为75.7%和94.6%。入院24 h内血清miR-193b-3p水平与入院时Hunt-Hess分级呈明显负相关（r=-0.384，P<0.001），与入院时Fisher分级呈明显负相关（r=-0.200，P=0.011），与入院时GCS评分呈明显正相关（r=0.409，P<0.001）。多因素logistic回归分析显示，入院24 h内血清miR-193b-3p≥0.62是aSAH病人预后不良的独立危险因素（OR=3.148；95% CI 1.017~5.167；P<0.001）。结论 本文结果提示入院24 h内血清miR-193b-3p作为非侵入性生物标志物，不仅可以用于评估aSAH病人的病情严重程度，还可以在早期用于预测病人的预后。
Abstract:
Objective To investigate the relationship between serum miR-193B-3P on admition and poor prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). Methods A total of 159 patients with aSAH were prospectively collected from January 1, 2019 to December 1, 2021, and the serum miR-193b-3p level within 24 h after admission was detected by RT-PCR. GOS score was used to evaluate the prognosis 90 days after the onset, with a GOS score of 4~5 as good prognosis and a GOS score of 1~3 as poor prognosis. Results Of these 159 patients, 153 patients had good prognosis, and 56 (35.2%) poor prognosis (39 patients died). ROC curve analysis showed that the area under the curve of serum miR-193b-3p level within 24 h after admission to predict the poor prognosis of aSAH patients was 0.912 (95%CI 0.870~0.954), the best cutoff value was 0.62, and the sensitivity and specificity were 75.7% and 94.6%, respectively. Serum miR-193b-3p levels within 24 h after admission were significantly negatively correlated with Hunt-Hess grade (r=-0.384, P<0.001) and Fisher grade on admission (r=-0.200, P=0.011), was significantly positive correlated with GCS score on admission (r=0.409, P<0.001). Multivariate logistic regression analysis showed that serum miR-193b-3p≥0.62 within 24 h after admission was an independent risk factor for poor prognosis of aSAH patients (OR=3.148; 95% CI 1.017~5.167; P<0.001). Conclusions Our results suggest that serum miR-193b-3p within 24 h of admission, as a non-invasive biomarker, can not only be used to assess the severity of aSAH patients, but also can be used to predict the prognosis of patients with aSAH in the early stage.

参考文献/References:

[1] NUSSBAUM ES, MIKOFF N, PARANJAPE GS. Cognitive deficits among patients surviving aneurysmal subarachnoid hemorrhage: a contemporary systematic review [J]. Br J Neurosurg, 2021, 35(4): 384-401.
[2] 中国研究型医院学会神经再生与修复专委会脑血管病学组. 动脉瘤性蛛网膜下腔出血：专家观点与规范推荐[J]. 中国血液流变学杂志，2019，29（3）：255-258.
[3] BALAN?A B, RITZENTHALER T, GOBERT F, et al. Significance and diagnostic accuracy of early S100B serum concentration after aneurysmal subarachnoid hemorrhage [J]. J Clin Med, 2020, 9(6): 1746-1756.
[4] LAI N, WU D, LIANG T, et al. Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice [J]. J Neuroinflammation, 2020, 17(1): 74-85.
[5] 朱艺琳，刘嘉棋，田　昊，等. 循环miRNA作为颅内动脉瘤生物标志物的研究进展[J]. 中华神经医学杂志，2022，21（12）：1269-1275.
[6] 蓝师海，洪　涛. miRNA与蛛网膜下腔出血关系的研究进展[J]. 中国临床神经外科杂志，2022，27（1）：48-50.
[7] YANG T, WU J, GE K, et al. MicroRNA-193b-3p reduces oxidative stress and mitochondrial damage in rats with cerebral ischemia-reperfusion injury via the seven in absentia homolog 1/Jun N-terminal kinase pathway [J]. Bioengineered, 2022, 13(3): 6942-6954.
[8] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组，中华医学会神经病学分会神经血管介入协作组. 中国蛛网膜下腔出血诊治指南2019[J]. 中华神经科杂志，2019，52（12）：1006-1021.
[9] CONNOLLY ES JR, RABINSTEIN AA, CARHUAPOMAJR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association [J]. Stroke, 2012, 43(6): 1711-1737.
[10] JENNETT B, BOND M. Assessment of outcome after severe brain damage [J]. Lancet, 1975, 1(7905): 480-484.
[11] 齐　猛，曲　鑫，徐跃峤，等. 老年重症动脉瘤性蛛网膜下腔出血患者预后的影响因素分析[J]. 中国脑血管病杂志，2020，17（1）：11-16.
[12] CHEN J, LI M, ZHU X, et al. Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults [J]. Aging, 2020, 12(3): 2939-2951.
[13] MISHRA R K, MAHAJAN C, KAPOOR I, et al. Comparison of Full Outline of UnResponsiveness (FOUR) score and the conventional scores in predicting outcome in aneurysmal subarachnoid haemorrhage patients [J]. Indian J Anaesth, 2019, 63(4): 295-299.
[14] RAJAJEE V. Grading scales in subarachnoid hemorrhage many options, but do we have a winner [J]. Eur J Neurol, 2018, 25(2): 207-208.
[15] WESTERN E, SORTEBERG A, BRUNBORG C, et al. Prevalence and predictors of fatigue after aneurysmal subarachnoid hemorrhage [J]. Acta Neurochir (Wen), 2020, 162(12): 3107-3116.
[16] QIN L, WANG Y, XIE Z, et al. The role of ET-1 in early cerebral microcirculation changes after subarachnoid hemorrhage [J]. J Healthc Eng, 2022, 2022: 4592986-4592992.
[17] Zhou J, Guo P, Guo Z, et al. Fluid metabolic pathways after subarachnoid hemorrhage [J]. J Neurochem, 2022, 160(1): 13-33.
[18] MAKOWSKA M, SMOLARZ B, ROMANOWICZ H. micro-RNAs in Subarachnoid Hemorrhage (Review of Literature) [J]. J Clin Med, 2022, 11(15): 4630-4649.
[19] SLOTA JA, BOOTH SA. MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications [J]. Noncoding RNA, 2019, 5(2): 35-57.
[20] YANG Z, ZHUANG Q, HU G, et al. MORC4 is a novel breast cancer oncogene regulated by miR-193b-3p [J]. J Cell Biochem, 2019, 120(3): 4634-4643.
[21] 赵春艳，屠淑敏，薛　冰，等. 动脉瘤性蛛网膜下腔出血患者高压氧治疗后血清miR-193b-3p水平及其意义[J]. 中华航海医学与高气压医学杂志，2022，29（1）：102-107.

相似文献/References:

[1]郭　芳　张　铭　李中振　梁恩和.动脉瘤性蛛网膜下腔出血后分流依赖性脑积水的危险因素分析[J].中国临床神经外科杂志,2016,(02):73.[doi:10.13798/j.issn.1009-153X.2016.02.004]
　GUO Fang,ZHANG Ming,LI Zhong-zhen,et al.Risk factors related to shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage[J].,2016,(09):73.[doi:10.13798/j.issn.1009-153X.2016.02.004]
[2]邹志鹏　杨　海　夏军勇　张化明　张　华　魏　恒　马江红.行血管内治疗的高龄颅内动脉瘤患者脑血管痉挛的临床分析[J].中国临床神经外科杂志,2015,(07):401.[doi:10.13798/j.issn.1009-153X.2015.07.006]
　ZOU Zhi-peng,YANG Hai,XIA Jun-yong,et al.Clinical analysis of symptomatic cerebral vasospasm after endovascular treatment of ruptured cerebral aneurysms in patients of 70 and over 70 years[J].,2015,(09):401.[doi:10.13798/j.issn.1009-153X.2015.07.006]
[3]郎胜坤　许厚银　董月青　马铁柱　孙　艳　郝芊芊　王慧敏.磁共振灌注成像评估蛛网膜下腔出血后脑血管痉挛的价值[J].中国临床神经外科杂志,2016,(09):517.[doi:10.13798/j.issn.1009-153X.2016.09.002]
　LANG Sheng-kuan,XU Hou-yin,DONG Yue-qing,et al.Evaluation of cerebral vasospasm after aneurysmal subarachnoid hemorrhage by magnetic resonance perfusion weighted imaging[J].,2016,(09):517.[doi:10.13798/j.issn.1009-153X.2016.09.002]
[4]王世龙,赵　冬,许　晖,等.血脂水平与动脉瘤性蛛网膜下腔出血后迟发性脑缺血的相关性[J].中国临床神经外科杂志,2016,(11):685.[doi:10.13798/j.issn.1009-153X.2016.11.011]
　WANG Shi-long,ZHAO Dong,XU Hui,et al.Relationship of serum lipid with delayed cerebral ischemia following the aneurysmal subarachnoid hemorrhage[J].,2016,(09):685.[doi:10.13798/j.issn.1009-153X.2016.11.011]
[5]潘逸珩　雷军荣　段　波　魏德胜　陈　亮　陈志明　秦　军.动脉瘤性蛛网膜下腔出血术后脑梗死的临床特点及其发生的危险因素分析[J].中国临床神经外科杂志,2017,(01):4.[doi:10.13798/j.issn.1009-153X.2017.01.002]
　PAN Yi-heng,LEI Jun-rong,DUAN Bo,et al.Analysis of clinical features of postoperative cerebral infarction and the factors related to it in patients with aneurysmal subarachnoid hemorrhage[J].,2017,(09):4.[doi:10.13798/j.issn.1009-153X.2017.01.002]
[6]谢　飞　陈志远　曾家良　叶勇强.DSA联合血清SICAM-1评估颅内破裂动脉瘤术后脑血管痉挛的效果[J].中国临床神经外科杂志,2017,(09):617.[doi:10.13798/j.issn.1009-153X.2017.09.003]
　XIE Fei CHEN Zhi-yuan ZENG Jia-liang,Ye Yong-qiang.Application of DSA combined with serum SICAM-1 to the evaluation of cerebral vasospasm after SAH due to aneurysmal rupture[J].,2017,(09):617.[doi:10.13798/j.issn.1009-153X.2017.09.003]
[7]阮　东　王　芳　郭丽蕊　彭红梅　陈谦学　刘宝辉.C-反应蛋白与动脉瘤性蛛网膜下腔出血临床预后的关系[J].中国临床神经外科杂志,2017,(09):626.[doi:10.13798/j.issn.1009-153X.2017.09.006]
　RUAN Dong,WANG Fang,GUO Li-rui,et al.Relationship between serum level of C-reactive protein and prognoses in patients with aneurysmal subarachnoid hemorrhage[J].,2017,(09):626.[doi:10.13798/j.issn.1009-153X.2017.09.006]
[8]阿库布千、李祥龙、罗　鑫、周　江、李　昊、刘　亮、 陈礼刚、夏祥国.亚洲人群动脉瘤性蛛网膜下腔出血高压氧辅助治疗疗效的Meta分析[J].中国临床神经外科杂志,2017,(11):757.[doi:10.13798/j.issn.1009-153X.2017.11.008]
　AKU Bu-qian,LI Xiang-long,LUO Xin,et al.Meta-analysis of effects of hyperbaric oxygen therapy on clinical outcomes in Asian patients with aneurysmal subarachnoid hemorrhage[J].,2017,(09):757.[doi:10.13798/j.issn.1009-153X.2017.11.008]
[9]张　兰　库洪彬　王　敏　周　燕.动脉瘤性蛛网膜下腔出血病人血清sLOX-1、netrin-1水平变化及其与病人预后的关系[J].中国临床神经外科杂志,2020,(06):377.[doi:10.13798/j.issn.1009-153X.2020.06.013]
　ZHANG Lan,KU Hong-bin,WANG Min,et al.Relationship between serum levels of sLOX-1 and netrin-1 and progosis of patients with aneurysmal subarachnoid hemorrhage[J].,2020,(09):377.[doi:10.13798/j.issn.1009-153X.2020.06.013]
[10]胡克琦　周达全　陈　锋　周　毅　敖祥生.miR-153下调FOXR2、CDK8和CDK13的表达抑制胶质母细胞瘤细胞增殖[J].中国临床神经外科杂志,2020,(11):767.[doi:doi:10.13798/j.issn.1009-153X.2020.11.011]
　HU Ke-qi,ZHOU Da-quan,CHEN Feng,et al.miR-153 inhibits proliferation of glioblastoma multiforme cell lines by down-regulation of FOXR2, CDK8 and CDK13[J].,2020,(09):767.[doi:doi:10.13798/j.issn.1009-153X.2020.11.011]

备注/Memo

备注/Memo:
（2023-04-20收稿，2023-05-22修回）
通讯作者：王新星，E-mail：wxxshy@163.com
更新日期/Last Update: 2022-09-30